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Although aspirin is commonly used for the prevention of cardiovascular disease, evidence from research 
has shown that these beneficial effects might extend to hepatocellular carcinoma (HCC). This dose-
response analysis was performed to investigate the association between aspirin use and risk of HCC. A 
systematic search was conducted in MEDLINE/PubMed, SCOPUS, Cochrane, and Web of Science 
databases from inception up to 29th October 2019. DerSimonian and Laird Random-effects model was used 
to estimate pooled hazard ratios (HRs) from included studies. Overall, eight studies containing 2,604,319 
participants evaluating the association between aspirin use and risk of HCC were uncovered and included 
in the present meta-analysis. Pooled results of included studies showed a significant reduction in risk of 
HCC in participants who used aspirin (HR 0.59, 95% CI 0.47-0.75, Pheterogeneity=0.001, I
2=90%). In total, 
13636 cases of HCC detected during the follow-up period of these studies. Furthermore, linear dose-
response model showed an significant inverse association between aspirin dose and risk of HCC (exp (b) = 
0.994, p<0.001), while non-linear dose-response analysis revealed an even more robust association 
(Coef1=-0.008, p1=0.04, Coef2=0.033, p2=0.13). This systematic review and dose-response analysis 
identified significant inverse relation between aspirin and risk of HCC using both linear and non-linear 
models.  







Liver cancer is the sixth most prevalent cancer globally, with over 840,000 new cases reported in 2018 (1). 
Indeed, this malignancy remains a highly fatal disease, with European mean age-standardized survival rate 
at five years sitting at just 12% at present (2). Hepatocellular carcinoma (HCC) is the most common form 
of liver cancer, comprising approximately 70–85% of the total cases, and represents the third highest cause 
of cancer-related mortality worldwide (3). Given this considerable incidence rate, the identification of 
efficacious interventions or programs that could prevent, or indeed attenuate, disease onset and progression 
is of paramount importance. 
Aspirin, one of the most ubiquitously consumed drugs worldwide, has proven benefits in the context of 
cardiovascular disease (4) and colorectal cancer (5-7), although there exists a paucity of chemoprotective 
evidence in relation to other cancers. In fact, the evidence has been conflicting at times, with trial data in 
discordance with observational findings at times. Schreinemachers and Everson initially reported that 
aspirin was associated with reductions in incidence of overall cancer, as well as breast, trachea, bronchus 
and lung cancer (8). Concordantly, Tsoi et al reported a significant reduction in cancer of the liver, stomach, 
colorectal, lung, pancreas, and oesophagus, as well as leukaemia following aspirin use (9). However, an 
11-year-long randomised control trial (RCT) of 39,876 US women, reported no beneficial effects associated 
with aspirin use and all forms of cancer (10). In addition, some evidence exists which suggests that aspirin 
may be effective only in the prevention of certain types of cancer; for instance, Flossmann et al reported a 
beneficial effect only for colorectal cancer (11).  
Although empirical evidence has demonstrated that aspirin may be chemoprotective in the context 
of HCC (12-16), equivocality is ever-present. Such inconsistencies may be attributable to varying study 
designs or follow-up durations, in addition to relatively modest sample sizes, accompanied by wide 
confidence intervals, which makes consensus difficult to attain. Thus, in the current systematic review and 
dose-response analysis, we aimed to pool the evidence from cohort studies examining the effects of aspirin 





2.  Materials and methods  
2.1.  Search Strategy 
This systematic review was performed according to the Preferred Reporting Items for Systematic Review 
and Meta-analysis [PRISMA] Statements(17). A systematic literature search was conducted from inception, 
without time or language restrictions, in PubMed/MEDLINE (https://www.ncbi.nlm.nih.gov/pubmed), 
Scopus (https://www.scopus.com), Cochrane library (https://www.cochranelibrary.com/), and Web of 
Science databases (http://apps.webofknowledge.com) up to 29th October 2019. The Supplementary Table 
1 presents the search terms that were used in each database. Furthermore, the reference lists of relevant 
original and review studies were scrutinized to identify additional studies of relevance.  
2.2. Inclusion and exclusion criteria 
The following inclusion criteria were considered in this study: 1) Studies which report a retrospective or 
prospective design; 2) Studies which reported hazard ratio (HR), odds ratio (OR), or risk ratio (RR) for 
HCC based on aspirin use categories. Review papers, case reports, ecological studies, editorials, non-human 
studies, in vitro research, or letters without sufficient data were excluded from the present review. 
Furthermore, studies containing patients diagnosed with HCC at baseline were excluded also. In studies 
that reported multiple timepoints, data from the longest follow-up period was used in the meta-analysis. 
2.3.  Data extraction and quality assessment 
After removal of duplicated studies, screening was conducted by two authors independently based on title 
and abstract. Full texts of studies were examined by two authors (HKV and AS) and discrepancies between 
authors were resolved by a senior author (YZ). The following data were extracted from the included studies: 
first author`, location of study, year of publication, number of participants, number of cases, gender 
distribution of participants, mean age of participants, aspirin use and dose, length of follow up, fully 
adjusted model and 95% CIs of liver cancer risk. Finally, two authors evaluated the quality of the included 





2.4.  Statistical analysis 
The results of the included studies were combined by DerSimonian and Laird random effects model (19). 
Based on the included studies, the aspirin-naïve group was considered as the reference category. The fully 
adjusted model considered nine models in the combination of results.  The subgroup analysis was based on 
the type of cohort assessed, as each study was run in different populations (e.g., public population or 
population with liver disease, such as hepatitis or cirrhosis). In addition, Cochran Q test (P heterogeneity) 
and I2 statistic were used to evaluate heterogeneity among the included studies, while meta-regression based 
on the duration of follow-up was applied in order to identify the probable source of detected heterogeneity. 
Studies which reported sufficient data in terms of number of participants, number of cases, and dosage of 
aspirin were included in dose-response analysis. Restricted cubic splines with three knots at percentiles 
10%, 50%, and 90% of the distribution were applied to linear and non-linear dose-response analysis (20). 
We calculated the linearity curve of the meta-analysis by testing the null hypothesis that the coefficient of 
the second spline was equal to zero with GLST. Sensitivity analysis was performed to investigate the effect 
of each study on the overall analysis. Funnel plots, as well as Begg's and Egger's asymmetry tests were all 
used in order to detect any publication bias which may have existed. All statistical analyses were conducted 
by STATA 14.0 software and a p value <0.05 was considered significant. 
3. Results 
3.1.  Literature search 
The flow diagram of the search strategy is provided in Figure 1. After removing duplicate studies from the 
systematic search, 392 articles remained for screening. During title and abstract screening 346 irrelevant 
studies were excluded and 46 studies included in the full text screening.  From these, 38 studies were 
excluded as they did not meet the predefined inclusion criteria (Supplemental Table 2) and eight studies 
with 2,604,319 participants were ultimately included (21-28). 





Included studies were published between 2012 to 2019 (Table 1). All studies were conducted in both males 
and females, and the mean length of follow-up was 8.9 years. Out of the eight studies, five were conducted 
in the general population (21, 23, 24, 27, 28), while the remaining three were focused on patients with liver 
disease(22, 25, 26). One study was conducted in Hong Kong (21), one in Taiwan (22), three in US (23, 27, 
28), and the remaining three in South Korea (24-26). Quality assessment of the included articles was 
performed using NOS scores, in which most articles scored as having high quality (Supplemental Table 3). 
Three studies achieved a score of eight, while the remainder scored nine. The most commonly detected 
weakness of the included studies was in adjustment for perceived cofounders. 
3.3. Main results of the analysis 
Eight studies with 2,604,319 participants included in this dose-response analysis (21-28), the results of 
which were combined by DerSimonian and Laird random effects model. The combined results suggested a 
significant reduction in the risk of liver cancer in participants who used aspirin (HR 0.59, 95% CI 0.47-
0.75, Pheterogeneity=0.001, I
2=90%) (Fig. 2). There was a significant heterogeneity between results of included 
studies, but this heterogeneity refers to amount of effect size and all studies show reverse relation. In 
addition to that, all studies independently demonstrated a reduction in the risk of liver cancer. Four studies 
with total of 2,168,012 participants were included in the dose-response analysis (21, 22, 24, 27). The linear 
dose-response model showed a significant inverse association between aspirin dose and risk of liver cancer 
(exp (b) = 0.994, p<0.001) (Fig. 3). Furthermore, the non-linear dose-response analysis revealed a 
comparable association (Coef1=-0.008, p1=0.04, Coef2=0.033, p2=0.13) (Fig. 4). Non-linear graph shows 
aspirin to have effective at doses up to around 100 mg per day, after which higher doses do not confer a 
further significant effect on HCC incidence. 
3.4. Sub-grouped analysis and meta-regression 
Results of the subgroup analyses and meta-regression are summarized in Supplemental Figure 1. We 





as hepatitis or cirrhosis). Subgroup analyses did not show a significant difference in risk of liver cancer 
(heterogeneity between groups p=0.29) between general populations (HR 0.60, 95% CI 0.56-0.63) and 
populations with liver disease (HR 0.66, 95% CI 0.55-0.80). Additionally, meta-regression based on the 
duration of follow-up was not significant for HCC either (coef = -0.0120072, p=0.51). 
3.5. Publication bias and Sensitivity analysis 
Funnel plot, Begg's rank correlation test, and Egger's regression asymmetry test were used to detect 
publication bias; however, the funnel plots did not reveal any asymmetry between the studies (Fig 5). 
Furthermore, Begg’s and Egger’s regression tests were not found to be significant either (p=0.21 and 
p=0.99, respectively). Finally, sensitivity analysis did not show any significant differences beyond the 
limits of 95% CI between calculated combined results (Supplemental Fig 2). 
4. Discussion 
Liver cancer is the sixth most prevalent cancer globally and the third most common cause of cancer-related 
death (3), with incidence and mortality rates ever-increasing (29). In vitro studies suggest that NSAIDs, 
such as aspirin, have preventive and therapeutic benefits for liver cancer (30, 31). Furthermore, human 
studies have yielded promising associations with aspirin use and the risk of liver cancer (32, 33). However, 
as of yet, no systematic compilation and dose-response analysis of available evidence has been performed. 
The principal findings of this study were that a significant reduction in risk of liver cancer was evident in 
participants who consumed aspirin. Moreover, linear and non-linear dose-response models showed a 
significant inverse association between aspirin dose and risk of liver cancer, with largely diminished returns 
at doses greater than 100 mg per day. 
The chemoprotective influence of aspirin has been documented in epidemiological evidence since 
the early 1980’s, with more contemporary evidence from the Physician’s Health Study (34), the Women’s 
Health Study (10), the UK Transient Ischaemic Attack Aspirin Trial (11), the British Doctors Aspirin Trial 





investigation which documented the impact of taking aspirin for 10 years, the authors reported absolute 
reductions in incidence of cancer from 0.76% in women to 2.51% in men (36). In the present study, included 
articles were contemporary, all being published between 2012 to 2019, and utilized an equitable split of 
both genders with an appropriately long mean follow-up (~9 years). Five out of eight studies were 
conducted in the general population (21, 23, 24, 27, 28) while the others included patients with liver disease 
(22, 25, 26). One study was conducted in Hong Kong (21), one in Taiwan (22), three in US (23, 27, 28), 
and three in South Korea (24-26).  
Eight studies with a sum total of 2,604,319 participants were included in this dose-response analysis 
(21-28). Five studies with 2,547,188 participants reported risk of liver cancer based on waist circumference 
(37-41). Results of the included studies were combined by DerSimonian and Laird random effects model 
and the combined results suggested a significant reduction in the risk of liver cancer in participants who 
used aspirin (HR 0.59, 95% CI 0.47-0.75, I2=90%) (Fig. 2). All studies also showed reduction in the risk of 
liver cancer independently. A clear inverse dose-response association was uncovered between aspirin 
dosing and development of liver cancer in both linear and non-linear models. Interestingly, we noted a 
substantially diminishment in this association once dosage exceeded 100 mg per day, suggesting that higher 
doses of the drug offered little in the way of additional chemoprotective benefits. Indeed, the analysis 
suggests that even daily consumption of the low-dose formulation aspirin (81 mg), which is typically 
prescribed prophylactically to those at risk of occlusive cardiovascular or cerebrovascular events, may 
achieve the majority of the desired beneficial effects. In addition, although not assessed within this analysis, 
use of such a dose may maintain a desired degree of safety, at least in those who do not represent a 
significant hemorrhagic risk. 
While there are a range of potential extrahepatic health benefits associated with low-dose aspirin 
ingestion, we now recognise that such regimens also carry with them a considerable potential for harm, 
particularly in certain at-risk populations. An important risk associated with sustained use of aspirin is 





gastrointestinal bleeding from esophageal varices or portal hypertensive gastropathy are prevalent clinical 
complications (42). Aspirin-induced bleeding can lead to catastrophic intracranial haemorrhage and therein 
also increase the risk of suffering from gastric ulceration and bleeding. Furthermore, high doses of the coxib 
NSAIDs is known to increase the thrombotic cardiovascular risk in a manner which is directly related to 
dose and age (43). 
Strength and limitations 
The main strength of this study is the incorporation of an extremely large sample size, consisting of over 
2.5 million participants. This provided findings that are generalizable and afforded the opportunity for 
subsequent dose-response analysis. The current study was found to be free of significant publication bias 
and is therefore unlikely to be substantially impacted by unpublished studies that returned negative results. 
The sample size used to generate the evidence reported in this systematic review is large; however, the 
results do not necessarily provide definitive findings of a causal inference due to the non-randomized 
design. In fact, as the studies contributing to this meta-analysis were all observational in design, we must 
consider the possibility of reverse causality and the healthy-person bias; that is to say, could individuals 
who are innately less prone to liver cancer, or those who are more cognizant of their overall health, be more 
likely to take aspirin as prophylaxis for other diseases?  
In a similar manner, it is indeed worth considering whether significant confounding factors may 
exist within the compiled studies. For instance, aspirin is commonly prescribed in conjunction with a 
hypocholesterolemic agent such as a statin, which in itself may reduce the risk of liver cancer in an 
individual (44). Unfortunately, although the consumption of other potentially chemoprotective agents 
(including other NSAIDs, statins, and metformin) was recorded and adjusted for in a number of the studies 
analyzed, several others explicitly outline that concomitant medications could not be assessed or excluded. 
Therefore, it is recommended that such studies be conducted in order to confirm the veracity of the findings 





was searched extensively, grey or unpublished literature was not explored to limit the possibility of 
publication bias. 
As aspirin is readily available in over-the-counter formulations, it is possible that the recorded 
consumption of the medication may have been an underestimated in the included studies. However, as self-
reporting was a prominent data collection method utilized in these studies rather than prescription records, 
it is less likely that underestimation occurred as a result of unrecorded over-the-counter doses. Although 
this method carries with it a degree of unavoidable recall bias. 
Regarding the potential for misclassification bias, the majority of studies included in this analysis 
utilized the International Classification of Diseases (ICD) 9 or 10, which brings consistency to the 
classification; although the means of diagnosis was not assessed and potentially differed between cohorts. 
Finally, as the populations assessed in these studies generally reported a mean age of greater than 60 years, 
a cohort which may suffer from an array of additional comorbidities, it is important to consider the impact 
of mortality as a competing risk. Indeed, just one of the eight studies included in this meta-analysis 




In the present meta-analysis, a significant reduction in risk of liver cancer was evident in participants who 
consumed aspirin. In addition, a significant inverse association between aspirin dose and risk of liver cancer 
was demonstrated, which displayed diminishing benefits at doses greater than 100 mg per day in non-linear 
analyses. This may have important clinical ramifications and adds support for the use of daily aspirin as a 
primary preventive strategy for liver cancer. However, as the studies included in this meta-analysis were 
all observational in nature, it is now essential that high-quality, large scale RCTs are conducted in order to 
prove the efficacy of such a regimen in a highly controlled context. Finally, given the potentially injurious 
side effects of prolonged aspirin use or use in bleed-risk populations, careful monitoring and supervision 






Conflict of interest statement 
The authors declare no conflict of interest. 
 
References 
1. Liver cancer 2018 [updated 2018/04/24/. Available from: https://www.wcrf.org/dietandcancer/liver-
cancer. 
2. De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, et al. Cancer survival in Europe 1999–
2007 by country and age: results of EUROCARE-5—a population-based study. The lancet oncology. 2014;15(1):23-
34. 
3. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: a cancer journal for 
clinicians. 2011;61(2):69-90. 
4. Preventive U. Services Task Force: Aspirin for the prevention of cardiovascular disease: US Preventive 
Services Task Force recommendation statement. Ann Intern Med. 2009;150(6):396-404. 
5. Algra AM, Rothwell PM. Effects of regular aspirin on long-term cancer incidence and metastasis: a 
systematic comparison of evidence from observational studies versus randomised trials. The lancet oncology. 
2012;13(5):518-27. 
6. Cole BF, Logan RF, Halabi S, Benamouzig R, Sandler RS, Grainge MJ, et al. Aspirin for the chemoprevention 
of colorectal adenomas: meta-analysis of the randomized trials. JNCI: Journal of the National Cancer Institute. 
2009;101(4):256-66. 
7. Rothwell PM, Price JF, Fowkes FGR, Zanchetti A, Roncaglioni MC, Tognoni G, et al. Short-term effects of 
daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits 
in 51 randomised controlled trials. The Lancet. 2012;379(9826):1602-12. 
8. Schreinemachers DM, Everson RB. Aspirin use and lung, colon, and breast cancer incidence in a prospective 
study. Epidemiology. 1994:138-46. 
9. Tsoi KK, Ho JM, Chan FC, Sung JJ. Long‐term use of low‐dose aspirin for cancer prevention: A 10‐year 
population cohort study in Hong Kong. International journal of cancer. 2019;145(1):267-73. 
10. Cook NR, Lee I-M, Gaziano JM, Gordon D, Ridker PM, Manson JE, et al. Low-dose aspirin in the primary 
prevention of cancer: the Women’s Health Study: a randomized controlled trial. Jama. 2005;294(1):47-55. 
11. Flossmann E, Rothwell PM. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from 
randomised and observational studies. The Lancet. 2007;369(9573):1603-13. 
12. Simon TG, Ma Y, Ludvigsson JF, Chong DQ, Giovannucci EL, Fuchs CS, et al. Association between aspirin use 
and risk of hepatocellular carcinoma. JAMA oncology. 2018;4(12):1683-90. 
13. Lee T-Y, Hsu Y-C, Tseng H-C, Yu S-H, Lin J-T, Wu M-S, et al. Association of daily aspirin therapy with risk of 
hepatocellular carcinoma in patients with chronic hepatitis B. JAMA internal medicine. 2019. 
14. Hwang IC, Chang J, Kim K, Park SM. Aspirin use and risk of hepatocellular carcinoma in a national cohort 
study of korean adults. Scientific reports. 2018;8(1):4968. 
15. Petrick JL, Sahasrabuddhe VV, Chan AT, Alavanja MC, Beane-Freeman LE, Buring JE, et al. NSAID use and 
risk of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: the liver cancer pooling project. Cancer 
Prevention Research. 2015;8(12):1156-62. 
16. Sahasrabuddhe VV, Gunja MZ, Graubard BI, Trabert B, Schwartz LM, Park Y, et al. Nonsteroidal anti -
inflammatory drug use, chronic liver disease, and hepatocellular carcinoma. JNCI: Journal of the National Cancer 
Institute. 2012;104(23):1808-14. 
17. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for 





18. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of 
nonrandomized studies in meta-analyses. European journal of epidemiology. 2010;25(9):603-5. 
19. Jackson D, White IR, Thompson SG. Extending DerSimonian and Laird's methodology to perform 
multivariate random effects meta‐analyses. Statistics in medicine. 2010;29(12):1282-97. 
20. Harre Jr FE, Lee KL, Pollock BG. Regression models in clinical studies: determining relationships between 
predictors and response. JNCI: Journal of the National Cancer Institute. 1988;80(15):1198-202. 
21. Tsoi KKF, Ho JMW, Chan FCH, Sung JJY. Long-term use of low-dose aspirin for cancer prevention: A 10-year 
population cohort study in Hong Kong. International Journal of Cancer. 2019. 
22. Lee TY, Hsu YC, Tseng HC, Yu SH, Lin JT, Wu MS, et al. Association of Daily Aspirin Therapy With Risk of 
Hepatocellular Carcinoma in Patients With Chronic Hepatitis B. JAMA Intern Med. 2019. 
23. Simon TG, Ma Y, Ludvigsson JF, Chong DQ, Giovannucci EL, Fuchs CS, et al. Association Between Aspirin Use 
and Risk of Hepatocellular Carcinoma. JAMA Oncol. 2018;4(12):1683-90. 
24. Hwang IC, Chang J, Kim K, Park SM. Aspirin Use and Risk of Hepatocellular Carcinoma in a National Cohort 
Study of Korean Adults. Scientific reports. 2018;8(1):4968.  
25. Oh S, Shin S, Lee S, Kim T, Nam S-J, Park J, et al. Aspirin and the risk of hepatocellular carcinoma 
development in patients with compensated alcoholic cirrhosis. Journal of Hepatology. 2017;66(1):S629-S30. 
26. Lee M, Chung GE, Lee JH, Oh S, Nam JY, Chang Y, et al. Antiplatelet therapy and the risk of hepatocellular 
carcinoma in chronic hepatitis B patients on antiviral treatment. Hepatology. 2017;66(5):1556-69. 
27. Petrick JL, Sahasrabuddhe VV, Chan AT, Alavanja MC, Beane-Freeman LE, Buring JE, et al. NSAID Use and 
Risk of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: The Liver Cancer Pooling Project. Cancer 
prevention research (Philadelphia, Pa). 2015;8(12):1156-62. 
28. Sahasrabuddhe VV, Gunja MZ, Graubard BI, Trabert B, Schwartz LM, Park Y, et al. Nonsteroidal anti-
inflammatory drug use, chronic liver disease, and hepatocellular carcinoma. Journal of the National Cancer Institute. 
2012;104(23):1808-14. 
29. McGlynn KA, London WT. The global epidemiology of hepatocellular carcinoma: present and future. C linics 
in liver disease. 2011;15(2):223-43. 
30. FODERÀ D, D'ALESSANDRO N, CUSIMANO A, POMA P, NOTARBARTOLO M, LAMPIASI N, et al. Induction of 
apoptosis and inhibition of cell growth in human hepatocellular carcinoma cells by COX‐2 inhibitors. Annals of the 
New York Academy of Sciences. 2004;1028(1):440-9. 
31. Leng J, Han C, Demetris AJ, Michalopoulos GK, Wu T. Cyclooxygenase-2 promotes hepatocellular carcinoma 
cell growth through Akt activation: evidence for Akt inhibition in celecoxib-induced apoptosis. Hepatology. 
2003;38(3):756-68. 
32. Coogan PF, Rosenberg L, Palmer JR, Strom BL, Zauber AG, Stolley PD, et al. Nonsteroidal anti -inflammatory 
drugs and risk of digestive cancers at sites other than the large bowel. Cancer Epidemiology and Prevention 
Biomarkers. 2000;9(1):119-23. 
33. Cibere J, Sibley J, Haga M. Rheumatoid arthritis and the risk of malignancy. Arthritis & Rheumatism: Official 
Journal of the American College of Rheumatology. 1997;40(9):1580-6. 
34. Gann PH, Manson JE, Glynn RJ, Buring JE, Hennekens CH. Low-dose aspirin and incidence of colorectal 
tumors in a randomized trial. JNCI: Journal of the National Cancer Institute. 1993;85(15):1220 -4. 
35. Burn J, Gerdes A-M, Macrae F, Mecklin J-P, Moeslein G, Olschwang S, et al. Long-term effect of aspirin on 
cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. The 
Lancet. 2011;378(9809):2081-7. 
36. Cuzick J, Thorat M, Bosetti C, Brown PH, Burn J, Cook N, et al. Estimates of benefits and harms of 
prophylactic use of aspirin in the general population. Annals of Oncology. 2014;26(1):47-57. 
37. Pang Y, Kartsonaki C, Guo Y, Chen Y, Yang L, Bian Z, et al. Central adiposity in relation to risk of liver cancer 
in Chinese adults: A prospective study of 0.5 million people. Int J Cancer. 2019. 
38. Wei L, Li N, Wang G, Feng X, Lyu Z, Li X, et al. Waist Circumference Might Be a Predictor of Primary Liver 
Cancer: A Population-Based Cohort Study. Frontiers in oncology. 2018;8:607. 
39. Lee J, Yoo SH, Sohn W, Kim HW, Choi YS, Won JH, et al. Obesity and hepatocellular carcinoma in patients 
receiving entecavir for chronic hepatitis B. Clinical and molecular hepatology. 2016;22(3):339-49. 
40. Campbell PT, Newton CC, Freedman ND, Koshiol J, Alavanja MC, Beane Freeman LE, et al. Body Mass Index, 





41. Schlesinger S, Aleksandrova K, Pischon T, Fedirko V, Jenab M, Trepo E, et al. Abdominal obesity, weight gain 
during adulthood and risk of liver and biliary tract cancer in a European cohort. Int J Cancer. 2013;132(3):645-57. 
42. Valkhoff VE, Sturkenboom MC, Kuipers EJ. Risk factors for gastrointestinal bleeding associated with low-
dose aspirin. Best Practice & Research Clinical Gastroenterology. 2012;26(2):125-40. 
43. Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ 
(Clinical research ed). 2000;321(7270):1183-7. 
44. Kim G, Jang SY, Nam CM, Kang ES. Statin use and the risk of hepatocellular carcinoma in patients at high 
risk: A nationwide nested case-control study. J Hepatol. 2018;68(3):476-84. 




Fig 2. Forest plot of Aspirin usage and risk of Liver Cancer, including eight individual studies and 2,604,319 
participants and overall hazard ratios, with respective weightings. Pooled results of included studies showed 
a significant reduction in risk of HCC in participants who used aspirin (HR 0.59, 95% CI 0.47-0.75, 
I2=90%). 
 
Fig 3. Linear dose-response relationship between Aspirin usage, in mg/day, and risk of Liver Cancer, 
presented as hazard ratio, with the associated exponential and p-value. The linear dose-response model 
showed a significant inverse association between aspirin dose and risk of liver cancer (exp (b) = 0.994, 
p<0.001). 
 
Fig 4. Non- linear dose-response relationship between Aspirin usage, in mg/day, and risk of Liver Cancer, 
presented as hazard ratio, with the resultant coefficient and p-value. The non-linear dose-response analysis 
revealed an inverse significant association (Coef=-0.008, p=0.04). 
 
Fig 5. Funnel plots, with pseudo 95% confidence intervals, of Aspirin usage and risk of Liver Cancer, 
presented with Egger’s and Begg’s test statistics, respectively  
